Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Astrocyte-intrinsic signaling of chitinase-like protein CHI3L1 drives inflammation and amplifies demyelination in neuromyelitis optica
Huiming Xu, Wei Jiang, Li Xu, Haoyang Li, Xin Yang, Fan Zhu, Pengyan He, Yanna Song, Yuhan Li, Yu-Wen Alvin Huang, Wei Qiu, Changyong Tang
Huiming Xu, Wei Jiang, Li Xu, Haoyang Li, Xin Yang, Fan Zhu, Pengyan He, Yanna Song, Yuhan Li, Yu-Wen Alvin Huang, Wei Qiu, Changyong Tang
View: Text | PDF
Research Article Autoimmunity Neuroscience

Astrocyte-intrinsic signaling of chitinase-like protein CHI3L1 drives inflammation and amplifies demyelination in neuromyelitis optica

  • Text
  • PDF
Abstract

Neuromyelitis optica (NMO) is an autoimmune disorder characterized by autoantibodies against the astrocyte water channel aquaporin-4 (AQP4) that cause demyelination in the optic nerves and spinal cord. How astrocytopathy leads to myelination deficits remains unclear. Chitinase-3–like protein 1 (CHI3L1, also known as YKL-40) is predominantly secreted by activated astrocytes, serves as a robust NMO biomarker, and plays a role in immune responses, but how it is induced and shapes astrocyte activation in NMO is not well defined. Using ex vivo and in vivo NMO mouse models together with mice with astrocyte-specific CHI3L1 knockout, we demonstrated that CHI3L1 directly contributed to demyelinating lesions elicited by AQP4 autoantibody–activated astrocytes. With complementary in vitro assays and inducible transgenic lines, we uncovered an astrocyte-intrinsic cascade in which AQP4 autoantibody exposure activated STAT3, which in turn drove CHI3L1 expression and secretion. Secreted CHI3L1 then engaged the astrocytic receptor RAGE in an autocrine manner, activating downstream NF-κB signaling that drove proinflammatory gliosis and damaged myelination. Pharmacological blockade of this pathway in NMO models rescued demyelinating pathology and improved motor function. These findings reveal an astrocyte-intrinsic CHI3L1 pathway that contributed to demyelination in NMO and identify actionable therapeutic targets.

Authors

Huiming Xu, Wei Jiang, Li Xu, Haoyang Li, Xin Yang, Fan Zhu, Pengyan He, Yanna Song, Yuhan Li, Yu-Wen Alvin Huang, Wei Qiu, Changyong Tang

×

Figure 5

Astrocytic STAT3 drives CHI3L1 induction and NF-κB activation to mediate NMO pathology.

Options: View larger image (or click on image) Download as PowerPoint
Astrocytic STAT3 drives CHI3L1 induction and NF-κB activation to mediate...
(A) KEGG pathway analysis of differentially expressed genes from primary astrocytes treated with AQP4-IgG versus Ctrl-IgG identifies JAK/STAT3 among the top pathways activated by AQP4 autoantibody exposure. (B) AQP4-IgG activates STAT3 and NF-κB and induces CHI3L1 in primary astrocytes; WP1066 (STAT3 inhibitor) suppresses p-STAT3, p-p65, and CHI3L1 levels. Immunoblot densitometry shown as CHI3L1/β-actin and phospho/total ratios for STAT3 and p65 (n = 3 experiments). (C) Cultures were treated with AQP4-IgG or Ctrl-IgG in the presence of FPS-ZM1 or sRAGE; no exogenous CHI3L1 was added. RAGE blockade (FPS-ZM1 or sRAGE) does not affect AQP4-IgG–evoked p-STAT3 but reduces p-p65, placing STAT3 upstream of CHI3L1/RAGE/NF-κB. Phospho/total immunoblot ratios are shown (n = 3 per group). (D) Model: AQP4-IgG triggers astrocytic STAT3 activation → CHI3L1 expression/secretion → autocrine engagement of RAGE → NF-κB–dependent proinflammatory signaling. (E) Conditional astrocyte-specific STAT3 knockout (STAT3 cKO): STAT3fl/fl × ALDH1L1-CreERT2 with tamoxifen induction, followed by systemic NMO paradigm (AQP4-IgG or Ctrl-IgG), behavioral testing, and spinal histopathology. (F) Efficiency of STAT3 depletion in astrocytes confirmed in striatum and L4 spinal cord by IHC (~80% reduction in STAT3 signal in GFAP+ cells) in STAT3-cKO versus STAT3fl/fl controls. Scale bar: 20 μm. (G) STAT3 cKO improves motor outcomes: gait (stride length) and rotarod latency across STAT3fl/fl + Ctrl-IgG, STAT3fl/fl + AQP4-IgG, STAT3 cKO + Ctrl-IgG, and STAT3 cKO + AQP4-IgG groups (n = 8 per group). Statistics: Data are mean ± SEM. Bar graph comparisons in B, C, and F used 1-way ANOVA with Tukey’s post hoc test or Welch’s ANOVA with Dunnett’s T3 test for unequal variances. Rotarod latency was analyzed by 2-way ANOVA (G). Non-significant comparisons are not shown. *P < 0.05; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts